semaglutide 25 mg side effects Ozempic face': Doctors explain effect of weight loss drugs Ozempic® (semaglutide) GLP-1 RA for

You can explore current opportunities through Be Part of Research, the NHS-backed clinical trial platform

A comprehensive literature search was conducted between January 1998 and May 2025 using PubMed/MEDLINE, Scopus, Cochrane CENTRAL, Clinicaltrials.gov, regulatory sources (EMA, FDA), and manual searches of high-impact journals ( NEJM , Lancet , JAMA , Diabetes Care , Obesity , Nature Medicine , Cell Metabolism )

Based on these convergent findings, we conclude that GABAergic inhibition in the PVN, driven by activation of OB Glp1r -expressing neurons, decreased sympathetic nerve activity to the pancreas, thereby increasing insulin release in WD mice

Simultaneously, the accumulation of autophagosomes within the ovary may trigger the death of granulosa cells and inhibit the developmental potential of oocytes

The effect of 2.4 mg once-weekly injected semaglutide in patients with HFpEF, obesity and T2D is currently investigated in an ongoing trial STEP-HFpEF DM (Semaglutide Treatment Effect in People with obesity and HFpEF and type 2 diabetes) (64, 65)

Metabolic and bariatric surgery should be discussed with patients who have BMI 35 kg/m (regardless of comorbidities) or BMI 30-34.9 kg/m with metabolic disease, according to 2022 ASMBS/IFSO guidelines